Epidermal Growth FactorEGF is part of a family of proteins that controls aspects of cell growth and development
The cells in your body constantly communicate with each other, negotiating the transport and use of resources and deciding when to grow, when to rest, and when to die. Often, these messages are carried by small proteins, such as epidermal growth factor (EGF), shown here in red from PDB entry 1egf . EGF is a message telling cells that they have permission to grow. It is released by cells in areas of active growth, then is either picked up by the cell itself or by neighboring cells, stimulating their ability to divide. The message is received by a receptor on the cell surface, which binds to EGF and relays the message to signaling proteins inside the cell, ultimately mobilizing the processes needed for growth.
Domains and Dimers
The EGF receptor, shown here in blue, is a flexible protein with many moving parts, including a large extracellular portion, a section that crosses the cell membrane, a kinase domain and a long flexible tail. The portion facing outwards from the cell, shown at the top here, is composed of four articulated domains that recognize EGF. When EGF is not around, it folds back on itself, as shown in the structure on the left. Then, when EGF binds, the receptor opens up and binds to another copy of the receptor, forming the dimeric complex shown on the right. This brings together two copies of the kinase domain, shown at the bottom here. Since the kinase domains are close to one another, they can add phosphate groups to tyrosine amino acids on the long, flexible tails of the receptor (the tails are not seen in this structure, so they are shown here with dots). The phosphorylated tails then stimulate the signaling proteins inside the cell.
Since the EGF receptor is so flexible, it has been studied by breaking it into several pieces and studying each one separately. Consequently, several PDB files were needed to create this illustration, including 1nql, 1ivo, 2jwa, 1m17 and 2gs6 . The structures of the different parts of the EGF receptor revealed several surprises. First of all, researchers found that EGF binds on either side of the receptor complex, not in the middle like other similar receptors. EGF appears to mold the receptor into the proper shape for dimerization, instead of acting like glue between the two chains. Also, careful analysis of the kinase domain showed that it is activated by association in an asymmetric head-to-tail fashion, in spite of the symmetric association of the extracellular portion.
EGF and the EGF receptor are part of an extended family of proteins that together control aspects of cell growth and development. These include at least seven similar protein messages, such as transforming growth factor alpha and amphiregulin, and four receptors, collectively termed ErbB or HER receptors. These messages and receptors can mix and match, with different messages bringing together two identical receptors or two different receptors. In this way, a wide variety of messages may be carried by the system, tailored for the needs of each type of cell.
Turning the Receptor Off
Of course, once a signal is sent through the EGF receptor, it eventually needs to be turned off. A separate enzyme performs this job by clipping off the phosphates that are added to the flexible tails of the receptor when it is activated. Protein tyrosine phosphatase 1B (PDB entry 1ptu ) is shown here (in orange), with a small piece of a phosphorylated protein chain bound in the active site. The phosphorylated tyrosine is buried deep in the active site.
Exploring the Structure
The signal carried by EGF can be dangerous if used improperly. Many forms of cancer circumvent the normal EGF signaling process, giving themselves permission to grow without control. Because of this, drugs that block EGF signaling are effective for the treatment of cancer. Two examples are shown here. At the left, the drug lapatinib is bound in the kinase domain of the receptor, blocking the signal inside the cell (PDB entry 1xkk ). It is very similar to the ATP used by the receptor, and binds tightly in the active site. Therapeutic antibodies are also used for cancer treatment. Herceptin is shown on the right bound to the extracellular domain of HER2/ErbB2 (PDB entry 1n8z), and the antibody cetuximab bound to the EGF receptor may be found in PDB entry . To explore these structures in more detail, click on the images for an interactive Jmol image.
Topics for Further Discussion
- Compare the mode of dimerization in the EGF receptor and the human growth hormone receptor.
- EGF receptor and similar receptors are currently the targets of development of drugs for cancer therapy. Can you find other examples of structures in the PDB with drugs?
June 2010, David Goodselldoi:10.2210/rcsb_pdb/mom_2010_6